



Patent Docket P0998D1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  Jeffrey L. Cleland et al.  Serial No.: 09/273,230  Filed: March 18, 1999  For: PROTEIN FORMULATION	Group Art Unit: 1642  Examiner: G. Bansal  <b>CERTIFICATE OF MAILING</b> I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on  August 28, 2000   Wendy Lee
--	--

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

Responsive to the Restriction Requirement mailed June 21, 2000, Applicants respectfully request the following:

In the Claims:

Please cancel claims 37-41 and 50.

REMARKS

Responsive to the Restriction Requirement mailed June 21, 2000, Applicants elect without traverse claims 42-49. Applicants elect species A. breast cancer. Claims 37-41 and 50 are cancelled. Claims 42-49 are pending.

Respectfully submitted,

GENENTECH, INC.

By:   
Wendy M. Lee  
Reg. No. 40,378

Date: August 28, 2000

1 DNA Way  
So. San Francisco, CA 94080-4990  
Phone: (650) 225-1994  
Fax: (650) 952-9881

RECEIVED  
SEP - 7 2000  
TC 1/00 MAIL ROOM

#613  
KA  
913-00